BusinessActinium Pharmaceuticals to Present at 19th Annual Bio€quity Europe Conference in Ghent, BelgiumBy Nasdaq OMXMay 8, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of DirectorsBy Nasdaq OMXMay 1, 2018, 11:31 AM UTC
BusinessActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical DevelopmentBy Nasdaq OMXApr 18, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual MeetingBy Nasdaq OMXApr 11, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform TechnologyBy Nasdaq OMXMar 28, 2018, 12:01 PM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory AffairsBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessActinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXMar 13, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Present at 30th Annual ROTH ConferenceBy Nasdaq OMXMar 7, 2018, 12:30 PM UTC
